Category: Clinical Trial Update Region: Europe · Switzerland Company: F Hoffmann La Roche Ag

Roches subcutaneous formulation of Tecentriq demonstrates positive Phase III results

By, Admin 1 min read
Share
Roches subcutaneous formulation of Tecentriq demonstrates positive Phase III results
Roche announced that the Phase III IMscin001 study evaluating a subcutaneous formulation of Tecentriq

Found this useful? Share it with your team.

Welcome Back Sign in to Continue

Don't Have an Account? Sign Up!
Forgot Password?

Create your Account!

Don't Have an Account? Sign Up!